A 48-year-old man is referred for evaluation. He has a history of hypercholesterolemia and obesity. Treatment with cholesterol-lowering medication was associated with elevated liver chemistries. When the elevated liver chemistries persisted
A 48-year-old man is referred for evaluation. He has a history of hypercholesterolemia and obesity. Treatment with cholesterol-lowering medication was associated with elevated liver chemistries. When the elevated liver chemistries persisted after cessation of the medication, imaging studies were obtained. Ultrasound and CT scan both revealed a heterogeneous mass in the head of the pancreas. There was dilatation of the main pancreatic duct in this area.
The patient denied abdominal pain, nausea, vomiting, and fever. He had a history of heavy alcohol use. There was no history of pancreatitis. Past medical history was positive only for hypercholesterolemia. Past surgical history was significant for cholecystectomy for gallstones 10 years earlier. Physical examination was unremarkable. Laboratory evaluation was normal except for mild elevation of alkaline phosphatase.
Endoscopic retrograde cholangiopancreatography (ERCP) was performed to evaluate the abnormal findings and to rule out chronic pancreatitis.
The correct answer to question 1 is d. The endoscopic photograph reveals the typical "fish eye" appearance of the main papilla seen with intraductal neoplasia of the pancreas and bile duct.
The correct answer to question 2 is b. Intraductal papillary mucinous tumor of the pancreas (IPMT), also known as intraductal papillary hyperplasia, mucinous ductal ectasia, mucin-producing tumor, and other names, was first reported by Ohashi and Maruyama in 1982. Since then, more than 300 cases of this rare entity have been reported worldwide.
It is characterized radiographically by cystic dilation of the main pancreatic duct or secondary branches with copious mucus secretion in the ductal lumen causing filling defects, and endoscopically by a swollen papilla extruding mucin.
The true incidence of IPMT in the population is unknown. One surgical study suggests that IPMT accounts for between 8% and 20% of pancreatic resections for malignancy. It is frequently found in men in the age range of 60 to 70 years; it is usually seen in the head of the pancreas but sometimes may involve the entire gland.
The etiology of IPMT is unclear. Environmental factors like tobacco and alcohol do not appear to play a significant role. There is no clear-cut genetic predisposition. Data from animal studies suggest nitroamines play a role in IPMT.
Common clinical manifestations include abdominal pain with features of acute and chronic pancreatitis secondary to intermittent obstruction of the main pancreatic duct, weight loss, anorexia, and steatorrhea. Diabetes, jaundice, and cholangitis can also occur. However, many patients are asymptomatic, and the tumor is found incidentally on imaging studies performed for unrelated problems.
A variety of imaging methods are available for the diagnosis of IPMT but none is superior, so a combination of methods is usually required for the diagnosis, with endoscopy and ERCP the most frequently used.
IPMT is a potentially curable disease if the lesion is resectable and has not metastasized. Total resection should be performed in main duct type (MDT)-IPMT tumors of any size originating in the main pancreatic duct, and local resection when IPMT is localized to a segment of the pancreas.
With branch duct type (BDT)-IPMT, total resection should be done when dilatation of the main duct is present even if the lesion is extremely small. However, if the lesion is less than 2.5 cm in diameter with a thin wall and normal main pancreatic duct, close monitoring with serial imaging studies can be done because these lesions are generally benign and growth is slow when it occurs.
The prognosis for patients who have undergone surgical resection for IPMT is good, with reports of 60% to 80% survival at 3 years in some studies. This is much better than survival for ductal adenocarcinoma of the pancreas. With invasive cancer, however, the 3-year disease-free survival decreases to as low as 21%. Overall, patients with BDT-IPMT do better than those with MDT-IPMT.
Farrell J, Brugge W: Intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc 55:701-714, 2002.
Hurwitz L, Daniels A, Barkin J, et al: Preoperative diagnosis of intraductal papillary mucinous tumors of the pancreas by endoscopic pancreatic biopsy. Gastrointest Endosc 53:510-513, 2001.